Romosozumab vs. Teriparatide in Postmenopausal Osteoporosis The effectiveness/safety of ROMO and TPTD were compared in a clinical setting, and ROMO showed greater increases in BMD than TPTD after 12 months of therapy, along with a higher completion rate. https://t.co/iKKLruiiay https://t.co/vPKa8pom7e